Ovarian/Peritoneal/Fallopian Tube Cancer

Show Only Open Trials
1.

Phase I Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Epithelial Cancer

  • Study Status: Open to Enrollment
  • Sponsor: Immunomedics
  • Disease Status and/or Stage: Metastatic Epithelial Cancer
2.

Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  • Study Status: Open to Enrollment
  • Sponsor: Millennium
  • Disease Status and/or Stage: Previously Treated, Metastatic Ovarian, Fallopian Tube or Primary Peritoneal Cancer
4.

A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: THE OUTBACK TRIAL

  • Study Status: Open to Enrollment
  • Sponsor: Gynecologic Oncology Group; National Cancer Institute
  • Disease Status and/or Stage: Locally Advanced Cervical Cancer
5.

Phase II Trial of Combination Pemetrexed (Alimta) and Carboplatin (Paraplatin) in Platinum Sensitive Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma

  • Study Status: Open to Enrollment
  • Sponsor: Montefiore Medical Center
  • Disease Status and/or Stage: Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
6.

A randomized phase III trial of paclitaxel plus carboplatin versus ifosfamide plus paclitaxel in chemotherapy naïve patients with newly diagnosed stage I-IV, persistent or recurrent carcinosarcoma (mixed mesodermal tumors) of the uterus or ovary

  • Study Status: Open to Enrollment
  • Sponsor: Gynecologic Oncology Group/NIH/NCI
  • Disease Status and/or Stage: Newly Diagnosed, Stage I-IV, Persistent or Recurrent Uterine or Ovarian Cancer
7.

A Phase II Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid and Islet Cell Cancer

  • Study Status: Open to Enrollment
  • Sponsor: Mayo Clinic, National Cancer Institute
  • Disease Status and/or Stage: Locally Advanced, Recurrant or Metastatic disease
8.

A Phase I Study of 177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-591) in Patients with Nonprostate Metastatic Solid Tumors: A Pilot Study

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Metastatic Solid Tumor

Top of page